Pfizer (NYSE: PFE), which has been cutting neuroscience research programs, sold the drug — currently known as PF-04958242 — for $75 million. Should Biogen succeed in bringing the drug to the market, Pfizer will make more from the deal. Should the drug hit certain commercialization milestones, …


Link to Full Article: Read Here

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!